Pfizer (NYSE:PFE) shares rose over 1% in pre-market trading Tuesday after the pharmaceutical giant beat Q4 earnings and revenue estimates while reaffirming its 2025 financial guidance.
Q4 Results
2025 Guidance & Cost Savings
Pfizer reaffirmed its 2025 financial guidance, projecting revenue between $61 billion and $64 billion (midpoint: $62.5 billion, slightly below the $63 billion consensus). Adjusted EPS is expected between $2.80 and $3.00 (midpoint: $2.90, just below the $2.93 consensus).
The company remains on track to achieve $4.5 billion in cost savings by year-end through its ongoing cost realignment program. CEO Albert Bourla stated that while 2024 focused on commercial effectiveness, 2025 will emphasize R&D productivity, alongside continued efforts on margin expansion, commercial excellence, and shareholder-friendly capital allocation.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.